Abstract： Objective： To analyze the mechanism of Zhongfeng Kangfu Capsules in the treatment of cerebral infarction based on network pharmacology and experimental validation. Methods：The herbal components of Zhongfeng Kangfu Capsules were retrieved and their active ingredients were identified through TCMSP and HERB databases，and the corresponding target proteins of the active ingredients were obtained. Disease targets related to cerebral infarction were retrieved using the GeneCards database. The interaction relationships between the intersection targets of Zhongfeng Kangfu Capsules and cerebral infarction were analyzed using the STRING database，and component-target topological analysis was performed using Cytoscape3.9.1 software to screen core targets. Gene Ontology（GO）function and Kyoto Encyclopedia of Genes and Genomes（KEGG）pathway enrichment analyses were conducted on the core targets，and a "herbal medicine - component - core target" network was constructed using Cytoscape3.9.1 software to identify key active ingredients of Zhongfeng Kangfu Capsules in the treatment of cerebral infarction. Molecular docking validation was performed using AutoDock Vina software. A rat model of cerebral infarction induced by middle cerebral artery occlusion （MCAO）was established，and the model was intervened with Zhongfeng Kangfu Capsules formula. The intervention was compared with a core target signaling pathway inhibitor as a control， and after 14 days of intervention， neurological deficit scores were assessed in each group of rats. Levels of cerebral infarction-related inflammatory factors were detected by enzyme-linked immunosorbent assay（ELISA），brain tissue morphology was observed by hematoxylin and eosin（HE）staining，neuronal damage was observed by Nissl staining，and the expression levels of major core target proteins in the aorta were detected by real-time PCR and Western blot. Results：A total of 174 active ingredients and 350 potential targets of Zhongfeng Kangfu Capsules were identified， with quercetin， kaempferol， stigmasterol， 7- methoxy-2-methyl isoflavone，and β-sitosterol being the top five key active ingredients. Among the 51 core targets in the drug-disease intersection proteins， IL-6， TNF， AKT1， IL-1β， TP53， MMP9， PTGS2， CASP3， EGFR， and SRC were identified. Gene enrichment analysis yielded 1 107 GO functional entries and 197 KEGG pathways， indicating that the phosphatidylinositol 3-kinase（PI3K）-protein kinase B（AKT）， IL-17， HIF-1， and mitogenactivated protein kinase 1（MAPK1）pathways are closely related to cerebral infarction. Molecular docking showed that the core proteins have good binding ability with the corresponding components. Animal experiments validated the important core target signaling pathway PI3K-AKT，and the results showed that compared with the model group，the Zealonga scores of the high- and low-dose groups of Zhongfeng Kangfu Capsules were significantly lower（P＜0.05）. HE staining revealed that the pathological changes in the high- and low-dose groups of Zhongfeng Kangfu Capsules were significantly less severe than those in the model group， with uniform cell size， intact structure， and relatively mild interstitial edema. Nissl staining showed that the morphology of nerve cells in the brain tissue of the high- and low-dose groups of Zhongfeng Kangfu Capsules was restored，with a significantly higher number of Nissl bodies than in the model group. RT-PCR and Western blot detection results showed that compared with the model group，the expression levels of PI3K，AKT1，and TP53 in the high- and low-dose groups of Zhongfeng Kangfu Capsules were significantly lower（P＜ 0.05）. ELISA detection results showed that compared with the model group，the levels of IL-6，TNF，and IL-1β in the high- and low-dose groups of Zhongfeng Kangfu Capsules were significantly lower（P＜0.05）. Conclusion：The molecular mechanism of Zhongfeng Kangfu Capsules in treating cerebral infarction was predicted from the perspective of network pharmacology， and it was preliminarily confirmed that it can downregulate the expression of the core target signaling pathway PI3K-AKT and its downstream signals，providing theoretical and experimental basis for the basic and clinical research of Zhongfeng Kangfu Capsules.